Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.
Conference ProceedingsПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gharpure Radhika, Vegvari Carolin, Abdissa Alemseged, Alimi Yewande, Anyamba Assaf, Auerbach Jochen, Bett Bernard, Bird Brian H, Bob Ndeye Sakha, Breugelmans J Gabrielle, Clark Jessica, Cleaveland Sarah, Cramer Jakob, Dawa Jeanette, Fay Petra C, Formenty Pierre, Gerdts Volker, Gerken Keli N, Gitonga John, Groschup Martin, Heighway James, Johnson Sherry Ama Mawuko, Juma John, Kading Rebekah C, Kamau Maureen, Kerama Samuel, Lubisi Baratang Alison, Lutwama Julius, Luyimbazi Dick, Marami Dadi, Moore Sean M, Muturi Mathew, Mwangoka Grace, Ndiu Angela, Njenga M Kariuki, Njouom Richard, Nyakarahuka Luke, Nzietchueng Serge, Oloo Paul, Otiende Mark, Oyola Samuel, Paganini Lodovico Samuele, Pandit Pranav S, Punt Carine, Samy Abdallah M, Situma Silvia, Sneddon Heidi, Ten Bosch Quirine A, Tezcan-Ulger Seda, Thompson Peter N, Tildesley Mike, Tinto Bachirou, Vesga Juan F, Wichgers Schreur Paul P, Hart Peter
Аннотация
Rift Valley fever (RVF) is a zoonotic viral disease that causes epidemics and epizootics among humans and livestock, resulting in substantial health and socioeconomic consequences. Currently, there are no RVF vaccines licensed for humans, but several candidates show promise in early-stage development. Existing gaps in RVF epidemiological data and challenges associated with predicting RVF outbreak risk complicate the planning of efficacy studies, making the pathway to licensure for promising candidates unclear. In June 2024, the Coalition for Epidemic Preparedness Innovations (CEPI) convened a two-day workshop in Nairobi, Kenya, to discuss RVF epidemiology, modeling priorities, and specific gaps relevant to human RVF vaccine development. The workshop included representatives from multiple RVF-endemic countries, key global collaborators, and international health organizations. Workshop participants identified five key priorities: (1) Looking beyond outbreaks: There is a need to better characterize the complex One Health epidemiology of RVF and understand interepidemic persistence of the virus; (2) Better data for better models: Epidemiological modeling is crucial for research, prediction, and planning, but it requires accurate and representative data; (3) New, improved and accessible diagnostics and serological assays: These are needed to inform epidemiology and case definitions, without which RVF research will continue to suffer due to paucity of data and challenges in determining infection and exposure; (4) Defining use cases, regulatory pathways, and implementation strategies for human vaccines: Clarity on these topics will facilitate licensure and effective use of RVF vaccines; and (5) People-centered approaches: Community engagement and involvement of social and behavioral scientists are key to the success of human vaccine research and development and implementation, particularly as the virus impacts livestock and livelihoods. Workshop participants welcomed a renewed focus for RVF epidemiology and modeling, and expressed enthusiasm for continued multidisciplinary collaborations to support enabling sciences for human RVF vaccine research and development.